Evotec SE (EVT.DE)

9,52 -0,12 (-1,30%) Al cierre: 05:42PM CEST

Evotec SE

Essener Bogen 7
Hamburg 22419
Germany
49 40 560 81 0
https://www.evotec.com

Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 5061

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Mario Polywka DPHIL, Ph.D.	CEO & Chairman of the Management Board & Member of the Supervisory Board	60k	N/A	1963
Dr. Cord Dohrmann Ph.D.	Chief Scientific Officer & Member of Management Board	582k	N/A	1964
Dr. Craig Johnstone Ph.D.	COO & Member of Management Board	712k	N/A	1970
Dr. Matthias Evers Ph.D.	Chief Business Officer & Member of Management Board	130k	N/A	1973
Ms. Laetitia Rouxel	CFO & Member of Management Board	890k	N/A	1975
Ms. Anja Bosler	Principal Accounting Officer and Senior Vice President of Group Accounting	N/A	N/A	N/A
Mr. Volker Braun	Executive VP and Head of Global Investor Relations & ESG	N/A	N/A	N/A
Dr. Christian Dargel	EVP Global Head of Legal & Compliance	N/A	N/A	N/A
Gabriele Hansen	Senior VP & Head of Global Corporate Communications & Marketing	N/A	N/A	N/A
Dr. Ian M. Hunneyball	Senior Vice President of Programme Management & Clinical Operations	116k	N/A	1950

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Gobierno corporativo

El ISS Governance QualityScore de Evotec SE, a día 1 de mayo de 2024, es 6. Las puntuaciones base son Auditoría: 4; Tablero: 4; Derechos de los accionistas: 1; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.